SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models

Table 1 The docking score for the six ERα antagonists

	6ZOQ-lig	4-hydroxy tamoxifen	SCR6139	SCR6515	Fulvestrant	SCR6852
DS^*(kcal/mol)	− 8.85	− 6.83	− 9.72	− 11.17	− 9.59	− 10.38

ISSN: 1465-542X